Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
New leadership team announced at NATHEALTH Annual General Meeting 2024
This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
The average time of dilation lasts three to eight hours
Lunaphore's flagship COMET technology is the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities
This acquisition enables MTD to open new, strategic markets
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
Subscribe To Our Newsletter & Stay Updated